Cg Oncology, Common Stock Fundamentals
| CGON Stock | 33.90 0.05 0.15% |
CG Oncology, Common fundamentals help investors to digest information that contributes to CG Oncology,'s financial success or failures. It also enables traders to predict the movement of CGON Stock. The fundamental analysis module provides a way to measure CG Oncology,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CG Oncology, stock.
CGON |
CG Oncology, Common Company Shares Owned By Insiders Analysis
CG Oncology,'s Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current CG Oncology, Shares Owned By Insiders | 7.04 % |
Most of CG Oncology,'s fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CG Oncology, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 7.04% of CG Oncology, Common are shares owned by insiders. This is 53.62% lower than that of the Biotechnology sector and 50.35% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 30.23% higher than that of the company.
CG Oncology, Common Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CG Oncology,'s current stock value. Our valuation model uses many indicators to compare CG Oncology, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CG Oncology, competition to find correlations between indicators driving CG Oncology,'s intrinsic value. More Info.CG Oncology, Common is rated fourth in operating margin category among its peers. It is the top company in current valuation category among its peers . At this time, CG Oncology,'s Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CG Oncology,'s earnings, one of the primary drivers of an investment's value.CGON Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CG Oncology,'s direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CG Oncology, could also be used in its relative valuation, which is a method of valuing CG Oncology, by comparing valuation metrics of similar companies.CG Oncology, is currently under evaluation in shares owned by insiders category among its peers.
CGON Fundamentals
| Operating Margin | (42.47) % | ||||
| Current Valuation | 1.83 B | ||||
| Shares Outstanding | 66.64 M | ||||
| Shares Owned By Insiders | 7.04 % | ||||
| Shares Owned By Institutions | 72.11 % | ||||
| Number Of Shares Shorted | 5.6 M | ||||
| Price To Book | 4.22 X | ||||
| Price To Sales | 4,451 X | ||||
| Revenue | 204 K | ||||
| EBITDA | (55.43 M) | ||||
| Net Income | (48.61 M) | ||||
| Total Debt | 461 K | ||||
| Cash Flow From Operations | (45.68 M) | ||||
| Short Ratio | 4.11 X | ||||
| Target Price | 68.2 | ||||
| Number Of Employees | 61 | ||||
| Market Capitalization | 2.4 B | ||||
| Total Asset | 199.3 M | ||||
| Retained Earnings | (129.94 M) | ||||
| Working Capital | 179.87 M | ||||
| Net Asset | 199.3 M |
About CG Oncology, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CG Oncology, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CG Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CG Oncology, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.80 | 1.60 | |
| Total Revenue | 204 K | 193.8 K | |
| Cost Of Revenue | 45.8 M | 48 M | |
| Stock Based Compensation To Revenue | 7.49 | 7.86 | |
| Sales General And Administrative To Revenue | 48.53 | 50.96 | |
| Research And Ddevelopement To Revenue | 224.27 | 235.49 | |
| Capex To Revenue | 0.07 | 0.03 | |
| Revenue Per Share | 0.05 | 0.08 | |
| Ebit Per Revenue | (271.81) | (285.40) |
Pair Trading with CG Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to CG Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology, Common to buy it.
The correlation of CG Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CG Oncology, Piotroski F Score and CG Oncology, Altman Z Score analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.036 | Quarterly Revenue Growth 1.727 |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.